PDF(Pubmed)
Abstract：
The placenta plays a key role in several adverse obstetrical outcomes, such as preeclampsia, intrauterine growth restriction and gestational diabetes mellitus. The early identification of at-risk pregnancies could significantly improve the management, therapy and prognosis of these pregnancies, especially if these at-risk pregnancies are identified in the first trimester. The aim of this review was to summarize the possible biomarkers that can be used to diagnose early placental dysfunction and, consequently, at-risk pregnancies. We divided the biomarkers into proteins and non-proteins. Among the protein biomarkers, some are already used in clinical practice, such as the sFLT1/PLGF ratio or PAPP-A; others are not yet validated, such as HTRA1, Gal-3 and CD93. In the literature, many studies analyzed the role of several protein biomarkers, but their results are contrasting. On the other hand, some non-protein biomarkers, such as miR-125b, miR-518b and miR-628-3p, seem to be linked to an increased risk of complicated pregnancy. Thus, a first trimester heterogeneous biomarkers panel containing protein and non-protein biomarkers may be more appropriate to identify and discriminate several complications that can affect pregnancies.
摘要：
胎盘在几种不良产科结局中起着关键作用，如先兆子痫，宫内生长受限和妊娠期糖尿病。及早发现高危妊娠可显著改善管理,这些怀孕的治疗和预后，特别是如果这些高危妊娠是在妊娠早期发现的.这篇综述的目的是总结可用于诊断早期胎盘功能障碍的可能的生物标志物，因此,有风险的怀孕。我们将生物标志物分为蛋白质和非蛋白质。在蛋白质生物标志物中，有些已经在临床实践中使用，如sFLT1/PLGF比率或PAPP-A；其他尚未验证，如HTRA1、Gal-3和CD93。在文学中,许多研究分析了几种蛋白质生物标志物的作用，但是他们的结果是相反的。另一方面,一些非蛋白质生物标志物，如miR-125b，miR-518b和miR-628-3p,似乎与复杂怀孕的风险增加有关。因此，包含蛋白质和非蛋白质生物标志物的妊娠早期异质性生物标志物组可能更适合识别和区分可能影响妊娠的几种并发症.
